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E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 45Results: Zoledronic acid but not pamidronate has a cytotoxic
potential even at pharmacological dosage. Zoledronic acid does
not only induce apoptosis by inhibiting the Ras-pathway but
has also an anti-metastatic effect. Freshly prepared cd T cells con-
sisting mainly of Vd2 cells showed increased cytotoxicity against
bisphosphonate-treated pancreatic carcinoma cells. cd T cells
could be expanded fourfold by use of anti-CD3 and IL-2. However,
activated. cd T cells do not respond to bisphosphonates and kill
mainly in a Vd1 dependent manner.
Results: Our results demonstrate that zoledronic acid has a
direct apoptotic effect on pancreatic carcinoma cells and has
anti-metastatic properties. Tumor cells treated with zoledronic
acid are more susceptible against Vc9 Vd2 T cells, the most abun-
dant population of cd T cells in the peripheral blood. Treatment
with zoledronic acid for patients with pancreatic carcinoma
might be an option.
doi:10.1016/j.ejcsup.2006.04.109
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Background: Tetraspanins are involved in cell activation, prolif-
eration, adhesion, motility and cell fusion. Some members
including D6.1A are known to promote metastasis formation.
Overexpression of the tetraspanin D6.1A on a rat pancreatic ade-
nocarcinoma line BSp73AS (BSp73AS-D6.1A) is associated with
the formation of haemorrhagic ascites and can induce dissemi-
nated intravascular coagulation.
Methods: Angiogenesis was analysed by intravital microscopy
of the rat mesentery 6 days after intraperitoneal tumor cell
application and after co-culture of the mesentery with tumor
cells, supernatant of the tumor cells and tumor cell derived
exosomes.
Results: D6.1A expressing tumor cells induced strong angio-
genesis with vessels covering roughly 25% of the tumor area
as compared to 5% in BSp73AS tumors. Also mesenteric cells
displayed strikingly increased branching in co-cultures with
BSp73AS-D6.1A cells, supernatant thereof or tumor cell derived
exosomes. A D6.1A-specific antibody completely inhibited
BSp73AS-D6.1A-, but also BSp73AS-induced angiogenesis
in vivo and in vitro. This finding suggested the existence of
an additional antibody target that has been identified as prolif-
erating endothelial cells, which strongly upregulate D6.1A
expression.
Conclusion: Tumor derived D6.1A is a strong angiogenesis indu-
cer, that indicates for an angiogenic loop due to the striking
upregulation of D6.1A on endothelial cells. Because of the latter,
the antibody-mediated suppression of the angiogenesis likely
offers a very effective and selective drug.
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Background: Histone deacetylase inhibitors (HDACi) are novel
anti-tumor compounds currently being tested in clinical trials.
Our laboratory has previously shown that in cultured cells
HDACi-induced cell death was mediated by mitochrondrial dam-
age, cytochrome C release and Bid cleavage. However, it is pres-
ently unclear which apoptotic pathways are utilized by HDACi
in vivo, i.e. in a therapeutic setting. Moreover, it is poorly under-
stood how molecular events during anti-cancer drug-mediated
apoptosis relate to therapeutic outcome.
Methods: We have employed the murine El-myc B-cell lym-
phoma model to directly compare HDACi-induced cell death
in vitro with therapeutic efficacy in vivo. Our system comprises
lymphomas with defined genetic alterations in the apoptotic
machinery and the tumors can either be grown and treated
in culture or transplated into immunocompetent animals for
therapy studies. Using this system, we have identified key
apoptotic molecules that not only control sensitivity of cultured
lymphoma cells to HDACi, but also determine therapeutic
outcome.
Results: Overexpression of Bcl2, previously linked to treatment
failure in human cancers, conferred complete chemoresistance
in vitro and in vivo. Strikingly, the HDACi SAHA eradicated El-
myc lymphomas in a p53-independent manner, resulting in pro-
longed survival after SAHA treatment of p53/ lymphomas.
Constraining the cellular apoptotic program by genetic targeting
of Apaf-1, Caspase-9 and Bid impinged on in vitro sensitivity
and we are currently investigating whether this is associated with
tumor relapse and chemoresistance while animals are under
therapy.
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Introduction: The X-ray cross-complementing gene XRCC1 and
the excision repair cross-complementing group 2 gene ERCC2
(XPD) are involved in the repair of DNA modifications resulting
from DNA-damaging agents used in cancer therapy. Functional
